X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs GLENMARK PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA GLENMARK PHARMA GSK PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 67.3 22.6 298.3% View Chart
P/BV x 13.6 3.5 383.4% View Chart
Dividend Yield % 1.1 0.3 311.2%  

Financials

 GSK PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
GLENMARK PHARMA
Mar-17
GSK PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760993 277.9%   
Low Rs2,040729 279.7%   
Sales per share (Unadj.) Rs339.0325.5 104.1%  
Earnings per share (Unadj.) Rs41.439.3 105.4%  
Cash flow per share (Unadj.) Rs45.948.7 94.3%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %1.50.2 627.9%  
Book value per share (Unadj.) Rs242.9159.2 152.6%  
Shares outstanding (eoy) m84.70282.17 30.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.12.6 267.6%   
Avg P/E ratio x57.921.9 264.4%  
P/CF ratio (eoy) x52.317.7 295.5%  
Price / Book Value ratio x9.95.4 182.7%  
Dividend payout %84.55.1 1,660.3%   
Avg Mkt Cap Rs m203,280242,991 83.7%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m5,23416,408 31.9%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m28,71591,857 31.3%  
Other income Rs m545374 146.0%   
Total revenues Rs m29,26092,230 31.7%   
Gross profit Rs m5,05920,367 24.8%  
Depreciation Rs m3802,644 14.4%   
Interest Rs m22,373 0.1%   
Profit before tax Rs m5,22215,724 33.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m178-810 -22.0%   
Tax Rs m1,8923,827 49.4%   
Profit after tax Rs m3,50811,088 31.6%  
Gross profit margin %17.622.2 79.5%  
Effective tax rate %36.224.3 148.9%   
Net profit margin %12.212.1 101.2%  
BALANCE SHEET DATA
Current assets Rs m21,81568,746 31.7%   
Current liabilities Rs m15,99927,027 59.2%   
Net working cap to sales %20.345.4 44.6%  
Current ratio x1.42.5 53.6%  
Inventory Days Days6485 74.8%  
Debtors Days Days1996 19.6%  
Net fixed assets Rs m12,47524,132 51.7%   
Share capital Rs m847282 300.1%   
"Free" reserves Rs m19,72644,643 44.2%   
Net worth Rs m20,57344,925 45.8%   
Long term debt Rs m645,363 0.0%   
Total assets Rs m39,475117,639 33.6%  
Interest coverage x2,612.07.6 34,253.2%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.70.8 93.2%   
Return on assets %8.911.4 77.7%  
Return on equity %17.124.7 69.1%  
Return on capital %26.219.1 137.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56456,152 1.0%   
Fx outflow Rs m7,4298,084 91.9%   
Net fx Rs m-6,86548,068 -14.3%   
CASH FLOW
From Operations Rs m4,7286,574 71.9%  
From Investments Rs m-1,042-7,124 14.6%  
From Financial Activity Rs m-3,0665,432 -56.5%  
Net Cashflow Rs m6201,992 31.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 6.9 147.8%  
FIIs % 23.8 34.4 69.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 56,727 179.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal & Realty Stocks Drag(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.1% while the Hang Seng is down 0.5%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 16, 2018 11:51 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS